Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 4/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.33 |
| ▸ | BID | P55957 | 4/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.32 |
| ▸ | BAK1 | Q16611 | 3/20 | 0.32 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.32 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25997171 | 1.00 | LTB4R (0.40) | LTB4RCYSLTR2CYSLTR1BIDMCL1 | |
| SCHEMBL26062059 | 1.00 | LTB4R (0.40) | LTB4RCYSLTR2CYSLTR1BIDMCL1 | |
| SCHEMBL25997185 | 1.00 | LTB4R (0.40) | LTB4RCYSLTR2CYSLTR1BIDMCL1 | |
| SCHEMBL25997157 | 0.99 | LTB4R (0.38) | LTB4RCYSLTR2CYSLTR1PPARA | |
| SCHEMBL25997199 | 0.92 | LTB4R (0.34) | LTB4RPPARA | |
| SCHEMBL22921322 | 0.91 | LTB4R (0.48) | LTB4RPPARA | |
| SCHEMBL22921369 | 0.91 | LTB4R (0.48) | LTB4RPPARA | |
| SCHEMBL22921417 | 0.91 | LTB4R (0.48) | LTB4RPPARA | |
| SCHEMBL22921250 | 0.91 | LTB4R (0.48) | LTB4RPPARA | |
| SCHEMBL25997177 | 0.91 | LTB4R (0.38) | LTB4RCYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | LTB4R 854/4885CYSLTR2 221/4885CYSLTR1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.